14-7-2 ⓔ文献
Rastegar A, Kashgarian M: The clinical spectrum of tubulointerstitial nephritis. Kidney Int, 1998; 54: 313–327.
Kelly CJ, Neilson EG: Tubulointerstitial diseases. The Kidney (Brenner BM ed), Elsevier Saunders, 2012; 1332–1355.
厚生労働省：重篤副作用疾患別対応マニュアル 間質性腎炎 (尿細管間質性腎炎) 平成30年6月改定．http://www.pmda.go.jp/files/000224770.pdf
De Broe ME: Epidemiology and pathogenesis of analgesic–related chronic kidney disease. UpToDate (Last updated: Sep 27, 2018).
Airy M, Raghavan R, et al: Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant, 2013; 28: 2502–2509.
Perazella MA: Onco–nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol, 2012; 7: 1713–1721.
難病情報センター：IgG関連疾患 (指定難病300)．https://www.nanbyou.or.jp/entry/4505
Moe OW: Posing the question again: Does chronic uric acid nephropathy exist? J Am Soc Nephrol, 2010; 21: 395–397.
Johnson RJ, Nakagawa T, et al: Uric acid and chronic kidney disease: which is changing which? Nephrol Dial Transplant, 2013; 28: 2221–2228.
Eckardt KU, Alper S, et al: Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management–A KDIGO consensus report. Kidney Int, 2015; 88: 676–683.
Bleyer AJ, Kidd K, et al: Autosomal dominant tubulo–interstitial kidney disease. Adv Chronic Kidney Dis, 2017; 24: 86–93.
Schnaper HW: The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis, 2017; 24: 107–116.